分子乳腺成像在乳腺癌筛查与问题解决中的应用
美国28个以上州的立法要求放射科医生告知接受乳腺筛查钼靶检查的女性其乳腺密度,这增加了公众对补充筛查的兴趣,但放射科医生尚未就补充筛查模式达成共识。本文描述分子乳腺成像(MBI)如何与数字乳腺断层合成(DBT)、靶向超声和磁共振成像一起融入临床实践,并介绍作者基于患者乳腺癌风险的筛查算法,以及MBI作为问题解决工具的应用。
要点
- MBI因高敏感度和高特异度而受到关注,可用于致密乳腺女性的补充筛查。
- 作者采用DBT作为主要筛查模式,结合自动密度计算,对致密乳腺女性补充MR成像或MBI。
- MBI也用于解决复杂钼靶或超声后的临床指征,或不明原因体格发现的问题。
核心结论
- MBI可作为致密乳腺女性补充筛查的选项之一,并与DBT、靶向超声和MR成像共同融入临床实践;MBI也可作为问题解决工具用于复杂钼靶或超声后的评估或不明原因体格发现。
研究设计与样本
- 本文为来自pubmed(Radiographics)的文章,描述MBI在临床实践中的实施方面,包括临床工作流程、患者管理、放射性示踪剂给药和操作报销;作者描述了其以DBT为主要成像模式的乳腺癌筛查方法,并基于患者乳腺癌风险使用算法决定是否适合补充MR成像或MBI。
临床应用与阅片要点
- 作者的方法是使用DBT作为主要成像模式,辅以自动密度计算,并对致密乳腺女性补充功能成像技术如MR成像或MBI。
- 作者使用基于患者乳腺癌风险的算法来确定补充筛查采用MR成像或MBI是否合适。
- MBI也用作问题解决工具,用于评估复杂钼靶或超声后的临床指征,或不明原因体格发现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
In the United States, legislative actions in over 28 states require radiologists to notify women who undergo breast screening mammography of their breast density. This has led to increased public interest in supplemental screening, but radiologists have not come to a consensus on a supplemental screening modality. In choosing between the most common options, whole-breast ultrasonography (US) and magnetic resonance (MR) imaging, one must weigh the benefits and drawbacks of each modality, as increased cancer detection may be accompanied by increased examination costs and biopsy rates. There has been recent interest in molecular breast imaging (MBI) for supplemental screening because of its high sensitivity, as well as its high specificity. This article describes how MBI fits into clinical practice alongside digital breast tomosynthesis (DBT), targeted US, and MR imaging. The authors describe their approach to breast cancer screening, which uses DBT as the primary imaging modality. DBT is complemented by automated density calculations and supplemented with functional imaging techniques, including MR imaging or MBI, for women with dense breasts. An algorithm based on the patient's breast cancer risk is used to determine if either MR imaging or MBI for supplemental screening is appropriate. MBI is also used as a problem-solving tool for the evaluation of clinical indications following complex mammography or US, or for unexplained physical findings. This article describes aspects related to implementing MBI in clinical practice, including the clinical workflow, patient management, radioactive tracer administration, and procedure reimbursement. © RSNA, 2017.
引用
- Shermis RB, Redfern RE, Burns J, et al. Molecular Breast Imaging in Breast Cancer Screening and Problem Solving. Radiographics. 2017. PMID: 28898193. doi:10.1148/rg.2017160204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。